- Home
- APLT vs ECOR Comparison
APLT vs ECOR Comparison
Compare APLT & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- ECOR
- Stock Information
- Founded
- APLT 2016
- ECOR 2005
- Country
- APLT United States
- ECOR United States
- Employees
- APLT N/A
- ECOR N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- APLT Health Care
- ECOR Health Care
- Exchange
- APLT Nasdaq
- ECOR Nasdaq
- Market Cap
- APLT 37.5M
- ECOR 40.1M
- IPO Year
- APLT 2019
- ECOR 2018
- Fundamental
- Price
- APLT $0.33
- ECOR $6.02
- Analyst Decision
- APLT Buy
- ECOR Strong Buy
- Analyst Count
- APLT 7
- ECOR 2
- Target Price
- APLT $6.10
- ECOR $25.50
- AVG Volume (30 Days)
- APLT 2.3M
- ECOR 130.4K
- Earning Date
- APLT 04-14-2025
- ECOR 05-07-2025
- Dividend Yield
- APLT N/A
- ECOR N/A
- EPS Growth
- APLT N/A
- ECOR N/A
- EPS
- APLT N/A
- ECOR N/A
- Revenue
- APLT $455,000.00
- ECOR $25,182,000.00
- Revenue This Year
- APLT $3,031.87
- ECOR $32.20
- Revenue Next Year
- APLT $312.01
- ECOR $46.27
- P/E Ratio
- APLT N/A
- ECOR N/A
- Revenue Growth
- APLT N/A
- ECOR 57.09
- 52 Week Low
- APLT $0.30
- ECOR $5.02
- 52 Week High
- APLT $10.62
- ECOR $19.49
- Technical
- Relative Strength Index (RSI)
- APLT 36.05
- ECOR 33.07
- Support Level
- APLT $0.30
- ECOR $5.20
- Resistance Level
- APLT $0.38
- ECOR $6.47
- Average True Range (ATR)
- APLT 0.05
- ECOR 0.71
- MACD
- APLT -0.00
- ECOR 0.33
- Stochastic Oscillator
- APLT 17.19
- ECOR 49.26
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.